Propranolol in infantile hemangiomas

Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
Christine Leaute-Labreze

Abstract

Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH). Propranolol is indicated in infants less than 5months of age with an IH requiring systemic therapy: IH at life-threatening and/or functional risk, painful ulcerated IH and IH that may cause permanent disfigurement. Propranolol should be initiated by physicians who have expertise in the diagnosis, treatment and management of IH. In addition, the first intake and every escalation should be administrated in a controlled clinical setting where adequate facilities for handling of adverse reactions, including those requiring urgent measures, are available. Then a monthly monitoring with dose adjustment weight is mandatory by the family doctor. Parents should be informed of the risk of hypoglycaemia and bronchoconstriction, especially during respiratory infectious outbreaks. The recommended duration of treatment is 6months without tapering. Relapses are possible necessitating a second course of 3 to 6months of treatment.

References

Jun 14, 2008·The New England Journal of Medicine·Christine Léauté-LabrèzeAlain Taïeb
Jun 2, 2009·Plastic and Reconstructive Surgery·Michele BigorreHuguette Valette
Aug 27, 2009·Pediatrics·Véronique SansChristine Léauté-Labrèze
May 22, 2010·The Journal of Pediatrics·Juliette Mazereeuw-HautierChristine Bodemer
Mar 1, 2011·Journal of the American Academy of Dermatology·Mélanie Saint-JeanUNKNOWN Groupe de Recherche Clinique en Dermatologie Pédiatrique
May 17, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·C Léauté-LabrèzeK Ezzedine
Nov 5, 2011·European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [et Al] = Zeitschrift Für Kinderchirurgie·S Hernandez-MartinJ A Tovar
Mar 12, 2013·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·C Léauté-Labrèze
May 15, 2013·The British Journal of Dermatology·C K AhogoC Léauté-Labrèze
Sep 10, 2013·Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS·M de GraafS G M A Pasmans
Feb 19, 2015·The New England Journal of Medicine·Christine Léauté-LabrèzeJean-Jacques Voisard

❮ Previous
Next ❯

Citations

Feb 3, 2016·Seminars in Perinatology·Kay D BeharryJacob V Aranda
Dec 3, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·F HartmannK-M Thoms
Aug 29, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Franziska HartmannKai-Martin Thoms
Sep 29, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Franziska HartmannKai-Martin Thoms

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Journal of the American Academy of Dermatology
Mélanie Saint-JeanGroupe de Recherche Clinique en Dermatologie Pédiatrique
Journal of Wound, Ostomy, and Continence Nursing : Official Publication of the Wound, Ostomy and Continence Nurses Society
Clare Ceballos, Janet M Ramundo
Journal of the American Academy of Dermatology
Marlies de GraafSuzanne G M A Pasmans
Journal of Cutaneous Medicine and Surgery
Alexandra Balma-MenaElena Pope
Ophthalmic Plastic and Reconstructive Surgery
Gretta FridmanCharles Slonim
© 2022 Meta ULC. All rights reserved